MBF Therapeutics of Ambler raised more than $100,000 in new capital from private investors and converted existing debt and notes into equity in a $1.1 million investment round, according to President and CEO Thomas Tillett.
The company — whose name is an acronym for Man’s Best Friend — also formed a collaboration with the Wistar Institute, an international biomedical research organization based in Philadelphia.
“We are very excited about this opportunity which involves Wistar’s checkpoint inhibitor technology that turbocharges cancer vaccines,” Tillett said. “Checkpoint inhibitors are the hottest thing in cancer care today. To have the opportunity to take this leading-edge technology and translate it to the animal health market is really exciting.”
The first application of the technology will be for treating melanoma, a deadly form of skin cancer that afflicts one out of four dogs.
“There is a need among pet owners for affordable therapies because there are very few dog-specific melanoma treatments available,” Tillett said.
Melanoma affects humans and dogs through exposure to UV light. Treatment options for dogs are limited to surgery and traditional chemotherapy.
Read the full article here.